ClinicalTrials.gg
CompletedNCT01020877Updated Jun 29, 2010Results posted

Bioavailability of Metronidazole Vaginal Gel in Healthy Subjects

A Phase 1 interventional study of Metronidazole and Metronidazole in Healthy, sponsored by Teva Pharmaceuticals USA. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-06-29.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The primary object of this study was to evaluate the relative bioavailability of the test formulation of metronidazole vaginal gel with the already marketed reference formulation MetroGel-Vaginal Gel® in healthy adult female subjects.

Read the detailed description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA Bioequivalence Statistical Methods

02

Conditions studied

  • Healthy

Keywords

  • Bioequivalence
  • Healthy Subjects
  • Healthy, Normal Subjects
03

In context

Lead sponsor

Teva Pharmaceuticals USA is the lead sponsor of 176 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females, 18 years of age or older.
  • Good health as determined by lack of abnormalities in health assessments performed at screening.
  • Signed form, which meets all criteria of current FDA regulations.
  • If female and of child bearing potential prepared to abstain from sexual intercourse or use a reliable method of during the study (e.g. condom, IUD, oral or implanted hormonal contraceptives).
  • Weight within + 25% from normal for height and weight for body frame as described in Novum Standard Operating Procedures adapted from the "MetLife® Height and Weight Tablets", Copyright© 1993.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, lactating, or likely to become pregnant during the study.
  • History of allergy or sensitivity to metronidazole, or history of any drug or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
  • Significant history or current evidence of chronic infectious disease, system disorder or organ disorder.
  • History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
  • Presence of a medical condition requiring regular treatment with prescription drugs (other than or hormonal replacement therapy).
  • Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
  • Receipt of any drug as part of a research study within 30 days prior to dosing.
  • Drug or alcohol addiction requiring treatment in the past 12 months.
  • Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to dosing.
  • Positive test for , surface antigen or antibody.
  • Positive test results for drugs of abuse at screening.
  • Evidence of vulvovaginitis or cervicitis (e.g. Bacterial vaginosis, vaginal candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhea, or history of Herpes simplex or human papillomavirus).
  • Vulvar or vaginal conditions that may affect absorption of the drug.
  • abnormal findings on PAP smear within previous 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    1

    Metronidazole Vaginal Gel

    Drug: Metronidazole

  • Active comparator
    2

    MetroGel-Vaginal®

    Drug: Metronidazole

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax (Maximum Observed Concentration of Drug Substance in Plasma)

    Bioequivalence based on Cmax.

    Time frame: Blood samples collected over a 60 hour period.

  2. AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

    Bioequivalence based on AUC0-t.

    Time frame: Blood samples collected over a 60 hour period.

  3. AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

    Bioequivalence based on AUC0-inf.

    Time frame: Blood samples collected over a 60 hour period.

07

Results

Posted Mar 23, 2010

Participant flow

First Intervention
Participant flow — First Intervention
MilestoneTest (Metronidazole) FirstReference (MetroGel-Vaginal®) First
Started1919
Completed1919
Not completed00
Washout of 7 Days
Participant flow — Washout of 7 Days
MilestoneTest (Metronidazole) FirstReference (MetroGel-Vaginal®) First
Started1919
Completed1919
Not completed00
Second Intervention
Participant flow — Second Intervention
MilestoneTest (Metronidazole) FirstReference (MetroGel-Vaginal®) First
Started1919
Completed1819
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryCmax (Maximum Observed Concentration of Drug Substance in Plasma)

Bioequivalence based on Cmax.

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng/mL
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
ng/mLTest (Metronidazole)Reference (MetroGel-Vaginal®)
Cmax (Maximum Observed Concentration of Drug Substance in Plasma)281.111 ± 72.222257.194 ± 71.228
Statistical analysis
  • Test (Metronidazole) vs Reference (MetroGel-Vaginal®) · Ratio of the t/r geometric mean x 100: 110 · 90% CI 103 to 117Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)

Bioequivalence based on AUC0-t.

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng*h/mL
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
ng*h/mLTest (Metronidazole)Reference (MetroGel-Vaginal®)
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)5921.046 ± 1713.3165593.855 ± 1683.155
Statistical analysis
  • Test (Metronidazole) vs Reference (MetroGel-Vaginal®) · Ratio of the t/r geometric mean x 100: 106 · 90% CI 98.2 to 115Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.
PrimaryAUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)

Bioequivalence based on AUC0-inf.

Time frame:
Blood samples collected over a 60 hour period.
Reported as:
Mean · ng*h/mL
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
ng*h/mLTest (Metronidazole)Reference (MetroGel-Vaginal®)
AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)5989.237 ± 1737.7915693.259 ± 1735.116
Statistical analysis
  • Test (Metronidazole) vs Reference (MetroGel-Vaginal®) · Ratio of the t/r geometric mean x 100: 106 · 90% CI 97.6 to 115Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

Adverse events

Collected over Adverse event data was collected over the course of the study, which was approximately 2 weeks in duration. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test (Metronidazole)—0/38 (0%)10/38 (26.3%)
Reference (MetroGel-Vaginal®)—0/38 (0%)16/38 (42.1%)
Most frequent other events
Most frequent other events
EventTest (Metronidazole)Reference (MetroGel-Vaginal®)
HeadacheGeneral disorders6/388/38
NauseaGeneral disorders1/382/38
Blood in UrineGeneral disorders1/382/38
DiarrheaGeneral disorders0/382/38
Abdominal Pain/CrampsGeneral disorders2/380/38
Protein in UrineGeneral disorders0/382/38

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Test (Metronidazole) FirstReference (MetroGel-Vaginal®) FirstTotal
<=18 years000
Between 18 and 65 years191938
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Test (Metronidazole) FirstReference (MetroGel-Vaginal®) FirstTotal
Female191938
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Test (Metronidazole) FirstReference (MetroGel-Vaginal®) FirstTotal
Black4812
Caucasian131124
More Than One202
Region of Enrollment
Region of Enrollment(participants)Test (Metronidazole) FirstReference (MetroGel-Vaginal®) FirstTotal
United States191938
08

Study locations

1 site
  • Novum Pharmaceutical Research Services
    Pittsburgh, Pennsylvania 15206, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2001, a primary completion of Nov 2001 and a completion of Jan 2002. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 8 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2009
First posted
Nov 26, 2009
Start
Nov 2001
Primary completionActual
Nov 2001
CompletionActual
Jan 2002
Results first posted
Mar 23, 2010
Last update
Jun 29, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01020877
First posted
Nov 26, 2009
Start date
Nov 2001
Primary completion
Nov 2001
Completion
Jan 2002
Results posted
Mar 23, 2010
Last update
Jun 29, 2010

Study contacts

Shirley A Kennedy, MD
principal investigator · Novum Pharmaceutical Research Services

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion